Adenosine inhibits the release of interleukin-1beta in activated human peripheral mononuclear cells

Cytokine. 2005 Aug 21;31(4):258-63. doi: 10.1016/j.cyto.2005.05.002.

Abstract

The effects of adenosine and subtype-specific activators of adenosine receptors (A1, A2A, A2B and A3) were studied on the release of interleukin-1beta (IL-1beta) from peripheral mononuclear cells, monocytes and lymphocytes. In the cells activated by the protein kinase C specific phorbol ester (phorbol 12-myristate 13-acetate) and Ca(2+) ionophore (A23187) both adenosine and the subtype-specific receptor agonists, CPA (A1), CGS 21680 (A2A) and IB-MECA (A3) induced a concentration-dependent inhibition of IL-1beta release. The rank order of potency in the inhibition of IL-1beta release was CPA=CGS 21680>IB-MECA>adenosine>NECA (in the presence of A1, A2A and A3 receptor inhibitors). The inhibitory actions of CPA, CGS 21680 or IB-MECA were significantly reduced in the presence of DPCPX, ZM 243185 or MRS 1191 as subtype-specific antagonists on A1, A2A and A3 adenosine receptors, respectively. It can be concluded that adenosine inhibits the release of IL-1beta from the activated human peripheral mononuclear cells. In this process A1, A2A and A3 receptors are involved.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / analogs & derivatives
  • Adenosine / pharmacology*
  • Calcimycin / pharmacology
  • Humans
  • Interleukin-1 / blood*
  • Monocytes / drug effects*
  • Monocytes / metabolism
  • Phenethylamines / pharmacology
  • Purinergic P1 Receptor Agonists
  • Tetradecanoylphorbol Acetate / pharmacology

Substances

  • Interleukin-1
  • Phenethylamines
  • Purinergic P1 Receptor Agonists
  • 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine
  • Calcimycin
  • Adenosine
  • Tetradecanoylphorbol Acetate